Moore v. Covenant Care Ohio, Inc.

2014 Ohio 4113
CourtOhio Court of Appeals
DecidedSeptember 19, 2014
DocketL-13-1259
StatusPublished
Cited by3 cases

This text of 2014 Ohio 4113 (Moore v. Covenant Care Ohio, Inc.) is published on Counsel Stack Legal Research, covering Ohio Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Moore v. Covenant Care Ohio, Inc., 2014 Ohio 4113 (Ohio Ct. App. 2014).

Opinion

[Cite as Moore v. Covenant Care Ohio, Inc., 2014-Ohio-4113.]

IN THE COURT OF APPEALS OF OHIO SIXTH APPELLATE DISTRICT LUCAS COUNTY

Alicia Moore, etc. Court of Appeals No. L-13-1259

Appellant Trial Court No. CI0201202706

v.

Covenant Care Ohio, Inc., et al.

Defendants

[Westhaven Services Co., LLC, d/b/a DECISION AND JUDGMENT Omnicare Pharmacy, etc., Kelli Renee Jones, and Stephanie Weiss—Appellees] Decided: September 19, 2014

*****

Jeffrey C. Zilba and Corey L. Tomlinson, for appellant.

Martin T. Galvin and David A. Valent, for appellees.

SINGER, J.

{¶ 1} Appellant, Alicia Moore, personal representative of the estate of Juanita

Williams, appeals from the October 30, 2013 judgment of the Lucas County Court of Common Pleas granting summary judgment to appellee, Omnicare, Inc., and dismissing

the wrongful death action filed by appellant. Because we find that Omnicare owed a duty

to exercise reasonable care to Moore, we reverse and remand.

{¶ 2} Appellant brought a survivorship and wrongful death action for the benefit

of the estate of Williams, deceased, and her next of kin. Appellant alleged a breach of

pharmaceutical care owed to Williams when she was a resident at Fairview Skilled

Nursing and Rehabilitation Center. The named defendants included Covenant Care Ohio,

Inc., d/b/a Fairview Skilled Nursing and Rehabilitation Center; dispensing pharmacist,

Kelli Renee Jones; consulting pharmacist, Stephanie Weis; and appellees, Westhaven

Services Co., LLC d/b/a Omnicare Pharmacy of Northwest Ohio, and Omnicare, Inc.

(collectively hereinafter referred to as “Omnicare”).

{¶ 3} The following undisputed facts were submitted into evidence by the parties

through the affidavit of Brian Pratt, the pharmacy manager at Omnicare; the deposition of

Stephanie Weis; the deposition of Kelli Jones; the deposition of Tamara Pilaczynski, a

certified pharmacy technician; and the affidavit of Robert S. Litman, R.Ph., C.Ph., GCP,

a licensed pharmacist, with over 30 years of experience, in the states of Florida and Ohio,

a board-certified geriatric pharmacist, and an adjunct professor of geriatric medicine at

several universities.

{¶ 4} Williams became a resident at Fairview on March 28, 2011. On April 9,

2011, Kamal Nader Tadros Yoakim, M.D., became her physician and discontinued her

daily dosage of 3.5 mg of an anticoagulant medication, Coumadin/Warfarin (hereinafter

2. “Warfarin”), which had been dispensed in a combination dose of 2.5 mg and 1 mg. Dr.

Yoakim increased her daily dosage to 5.0 mg for two days and then ordered a daily

dosage of 4.0 mg of Warfarin to continue thereafter because of her history of deep vein

thrombosis and pulmonary embolism. The doctor further ordered that her blood be

drawn every Tuesday to measure her Prothrombin Time/International Normalized Ratio

(hereinafter “INR”) in order to determine the therapeutic effectiveness of the medication.

{¶ 5} Omnicare, Inc. became the provider of pharmaceutical medications to

Williams while she was at Fairview, through its subsidiary, Westhaven Services Co.,

LLC d/b/a Omnicare Pharmacy of Northwest Ohio. Jones was the dispensing pharmacist

for Omnicare who filled Williams’ new prescription for Warfarin. Jones testified that

computer-generated marks on the order form indicated that each element of the order was

entered into Omnicare’s computer system (“OASIS”) by a technician and was verified by

a pharmacist. However, the physician’s orders sheets (hereinafter “POS”) created by

Omnicare dated May 1 and June 1 continued to show pending prescriptions for Warfarin

of 2.5 mg, 1 mg, and 4 mg. Both Jones and Weis testified that while Omnicare produced

the POS, it was Fairview’s responsibility to correct or update the report and get the

physician’s signature. Jones could not explain why the May and June POS still indicated

pending prescriptions for Warfarin of 2.5 mg, 1 mg, and 4 mg.

{¶ 6} Omnicare’s records further indicated that 30 doses of 1 mg and 2.5 mg of

Warfarin had been shipped to Fairview on March 28, 2011, and two-5 mg doses of

Warfarin were shipped on April 10, 2011. The prescription for the 4 mg dose of

3. Warfarin was received by Omnicare and entered into OASIS on April 11, 2011.

However, the 4 mg doses were never shipped to Fairview.

{¶ 7} When Jones reviewed Williams’ POS dated May 1, 2011, she testified she

would have noticed that there were three orders for Warfarin of three different dosage

levels. The computer should have caught that these orders were conflicting and caused a

pop-up box to appear, which would have to be cleared before the computer could accept

the order. Jones could not recall having reviewed this particular POS in May 2011, but

the computer recorded that she was the verifying pharmacist. She also could not predict

whether a conflict would have alerted in June 2011.

{¶ 8} Jones does not routinely verify INR results before dispensing Warfarin.

Jones testified that Omnicare’s policy when an order for Warfarin is received is to verify

a room number or a birthday, match the doctor, review the strength and directions, and

determine whether there is a duplication of therapies. Another pharmacist at Omnicare

does review the INR results before dispensing Warfarin based on those results because he

is a Warfarin-dosing pharmacist whose services are specifically paid for by the facilities.

Jones would, however, check the INR parameters under certain circumstances such as

when antibiotics were dispensed or the patient was receiving bridging therapy between

anticoagulants. While Omnicare policy also provides that the pharmacist should review a

patient’s chart for existing Warfarin orders when a new anticoagulant order is received,

Jones testified that she does not review the charts, but reviews the patient’s profile in

OASIS.

4. {¶ 9} Williams received the 5.0 mg doses of Warfarin for two days. However,

after April 10, 2011, there is conflicting evidence as to whether Williams received her

daily 4.0 mg of Warfarin for the month of April. An anticoagulant administration and

billing record for Williams completed by the nurses indicates that Williams was given 4.0

mg of Warfarin from April 11-30, 2011. However, during a random sampling of medical

carts at Fairview on April 28, 2011, Pilaczynski, the pharmacy technician, determined

that Williams’ cart did not contain any Warfarin medication as prescribed. Pilaczynski

notified Williams’ nurse that same day. Pilaczynski testified it was not within her job

description to rectify the irregularity. After April 2011, it is undisputed that Williams did

not receive any Warfarin during the period of May through June, 2011.

{¶ 10} Pratt attested that Omnicare’s policy 4.5 was in effect at the time Williams

was a patient at Fairview and governed the re-ordering procedures for medication. This

policy required that Fairview contact Omnicare in order to request a refill of any

prescription and Fairview did not order any anticoagulation therapy refill for Williams

after April 9, 2011. Jones testified that she did not know whether OASIS sent warnings if

a drug was not shipped as ordered. She did not know if the pending 3.5 mg dose would

have some way interfered with the delivery of the 4 mg dose. The only explanation she

could give for the failure of the shipment of the 4 mg dose was Omnicare’s unwritten

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Riverside Drive Ents., L.L.C. v. Geotechnology, Inc.
2023 Ohio 583 (Ohio Court of Appeals, 2023)
Perez-Herrera v. Now Clinic
2023 Ohio 173 (Ohio Court of Appeals, 2023)
Kamnikar v. Fiorita
2017 Ohio 5605 (Ohio Court of Appeals, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
2014 Ohio 4113, Counsel Stack Legal Research, https://law.counselstack.com/opinion/moore-v-covenant-care-ohio-inc-ohioctapp-2014.